{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:15:04Z","timestamp":1789582504003,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012319","name":"Max Planck Institute for Dynamics of Complex Technical Systems Magdeburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004189","name":"Max-Planck-Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009584","name":"Toyota Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013826","name":"Candys Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006360","name":"Bundesministerium f\u00fcr Wirtschaft und Energie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008269","name":"L\u00e6ge Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002918","name":"Gentofte Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001825","name":"Danish Agency for Science and Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.isci.2023.105949","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T20:50:54Z","timestamp":1673297454000},"page":"105949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals"],"prefix":"10.1016","volume":"26","author":[{"given":"Anna","family":"Offersgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Rene","family":"Duarte Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Marichal-Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenn","family":"Holmbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Finne","family":"Pihl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Fernandez-Antunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garazi Pe\u00f1a","family":"Alzua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine Top","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long V.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Anbro","family":"Gammeltoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Fahn\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe Vest","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Kristian","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Elvang","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Pravsgaard","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santseharay","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-0256","authenticated-orcid":false,"given":"Judith Margarete","family":"Gottwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2023.105949_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.105949_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.isci.2023.105949_bib3","series-title":"Listings of WHO\u2019s Response to COVID-19","year":"2021"},{"key":"10.1016\/j.isci.2023.105949_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fpubh.2020.00241","article-title":"Economic consequences of the COVID-19 outbreak: the need for epidemic preparedness","volume":"8","author":"Pak","year":"2020","journal-title":"Front. Public Health"},{"key":"10.1016\/j.isci.2023.105949_bib5","series-title":"WHO Coronavirus (COVID-19) Dashboard","year":"2022"},{"key":"10.1016\/j.isci.2023.105949_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.105949_bib7","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2020.2565","article-title":"Presumed asymptomatic carrier transmission of COVID-19","volume":"323","author":"Bai","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2023.105949_bib8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/jcm10030446","article-title":"Multi-organ involvement in COVID-19: beyond pulmonary manifestations","volume":"10","author":"Thakur","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.isci.2023.105949_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","article-title":"Structural biology of SARS-CoV-2: open the door for novel therapies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2023.105949_bib10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.isci.2023.105949_bib11","series-title":"Novavax Statement on UK and Mexico Phase 3 Clinical Trial Participants Considered Fully Vaccinated in the US","year":"2021"},{"key":"10.1016\/j.isci.2023.105949_bib12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2023.105949_bib13","doi-asserted-by":"crossref","first-page":"e2130800","DOI":"10.1001\/jamanetworkopen.2021.30800","article-title":"Evaluation of a COVID-19 vaccine campaign and SARS-CoV-2 infection and mortality among adults aged 60 Years and older in a middle-income country","volume":"4","author":"Macchia","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.isci.2023.105949_bib14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.105949_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajem.2021.05.054","article-title":"Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines","volume":"49","author":"Long","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.isci.2023.105949_bib16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14760584.2021.1976153","article-title":"Impact of the Delta variant on vaccine efficacy and response strategies","volume":"20","author":"Bian","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.isci.2023.105949_bib17","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.105949_bib18","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.105949_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jmv.27334","article-title":"A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine","volume":"94","author":"Yue","year":"2022","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.isci.2023.105949_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","article-title":"Spike-antibody waning after second dose of BNT162b2 or ChAdOx1","volume":"398","author":"Shrotri","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.105949_bib21","doi-asserted-by":"crossref","first-page":"n2375","DOI":"10.1136\/bmj.n2375","article-title":"Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding","volume":"375","author":"Feinmann","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.isci.2023.105949_bib22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jama.2021.13226","article-title":"Making vaccines available to other countries before offering domestic booster vaccinations","volume":"326","author":"Schaefer","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2023.105949_bib23","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1016\/j.vaccine.2020.06.058","article-title":"Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity","volume":"38","author":"Henn","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.isci.2023.105949_bib24","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.mayocp.2020.07.021","article-title":"SARS-CoV-2 vaccine development: current status","volume":"95","author":"Poland","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.isci.2023.105949_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.105949_bib26","series-title":"Sinovac Says COVID-19 Vaccine Effective in Preventing Hospitalization, Death","year":"2021"},{"key":"10.1016\/j.isci.2023.105949_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2023.105949_bib28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","article-title":"China's COVID vaccines have been crucial - now immunity is waning","volume":"598","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2023.105949_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1473-3099(21)00674-5","article-title":"Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study","volume":"22","author":"Desai","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2023.105949_bib30","series-title":"Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001","year":"2022"},{"key":"10.1016\/j.isci.2023.105949_bib31","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1002\/jmv.27095","article-title":"Equal access of COVID-19 vaccine distribution in Africa: challenges and way forward","volume":"93","author":"Aborode","year":"2021","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.isci.2023.105949_bib32","article-title":"COVID-19 vaccines dampen genomic diversity of SARS-CoV-2: unvaccinated patients exhibit more antigenic mutational variance","author":"Niesen","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2023.105949_bib33","doi-asserted-by":"crossref","first-page":"e14062","DOI":"10.15252\/emmm.202114062","article-title":"SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time-course study - potential challenge for vaccines and therapies","volume":"13","author":"Weber","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.isci.2023.105949_bib34","series-title":"Tracking SARS-CoV-2 Variants","year":"2022"},{"key":"10.1016\/j.isci.2023.105949_bib35","doi-asserted-by":"crossref","first-page":"eabg3055","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 Lineage B.1.1.7 in England","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.isci.2023.105949_bib36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2023.105949_bib37","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","article-title":"Nextstrain: real-time tracking of pathogen evolution","volume":"34","author":"Hadfield","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.isci.2023.105949_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/d41586-021-03552-w","article-title":"Heavily mutated Omicron variant puts scientists on alert","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2023.105949_bib39","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/d41586-022-01730-y","article-title":"What Omicron's BA.4 and BA.5 variants mean for the pandemic","volume":"606","author":"Callaway","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2023.105949_bib40","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron","volume":"602","author":"Carre\u00f1o","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2023.105949_bib41","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jmv.27541","article-title":"Omicron (B.1.1.529): a new SARS-CoV-2 variant of concern mounting worldwide fear","volume":"94","author":"Thakur","year":"2022","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.isci.2023.105949_bib42","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/vaccines9070706","article-title":"SARS-CoV-2 production in a scalable high cell density bioreactor","volume":"9","author":"Offersgaard","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.isci.2023.105949_bib43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.chroma.2016.12.076","article-title":"Steric exclusion chromatography for purification of cell culture-derived influenza A virus using regenerated cellulose membranes and polyethylene glycol","volume":"1483","author":"Marichal-Gallardo","year":"2017","journal-title":"J.\u00a0Chromatogr. A"},{"key":"10.1016\/j.isci.2023.105949_bib44","doi-asserted-by":"crossref","first-page":"16261","DOI":"10.1038\/s41598-020-72328-5","article-title":"Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine","volume":"10","author":"Lothert","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2023.105949_bib45","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1089\/hum.2019.284","article-title":"Single-use capture purification of adeno-associated viral gene transfer vectors by membrane-based steric exclusion chromatography","volume":"32","author":"Marichal-Gallardo","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.isci.2023.105949_bib46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12915-021-01020-5","article-title":"Cell culture-based production and in\u00a0vivo characterization of purely clonal defective interfering influenza virus particles","volume":"19","author":"Hein","year":"2021","journal-title":"BMC Biol."},{"key":"10.1016\/j.isci.2023.105949_bib47","doi-asserted-by":"crossref","first-page":"e0009721","DOI":"10.1128\/AAC.00097-21","article-title":"Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication","volume":"65","author":"Ramirez","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2023.105949_bib48","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s11095-008-9559-6","article-title":"Development of stable influenza vaccine powder formulations: challenges and possibilities","volume":"25","author":"Amorij","year":"2008","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.isci.2023.105949_bib49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.isci.2023.105949_bib50","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.isci.2023.105949_bib51","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2023.105949_bib52","doi-asserted-by":"crossref","first-page":"32657","DOI":"10.1073\/pnas.2014468117","article-title":"A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine","volume":"117","author":"H\u00f6rner","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2023.105949_bib53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.actatropica.2015.08.018","article-title":"Cross reactive molecules of human lymphatic filaria Brugia malayi inhibit Leishmania donovani infection in hamsters","volume":"152","author":"Verma","year":"2015","journal-title":"Acta Trop."},{"key":"10.1016\/j.isci.2023.105949_bib54","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/eji.200838389","article-title":"Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis","volume":"39","author":"Kumari","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2023.105949_bib55","doi-asserted-by":"crossref","first-page":"113756","DOI":"10.1016\/j.jviromet.2019.113756","article-title":"Membrane-based steric exclusion chromatography for the purification of a recombinant baculovirus and its application for cell therapy","volume":"275","author":"Lothert","year":"2020","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.isci.2023.105949_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2023.105949_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2023.105949_bib58","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2023.105949_bib59","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jhep.2021.12.026","article-title":"Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice","volume":"76","author":"Pihl","year":"2022","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.isci.2023.105949_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.isci.2023.105949_bib61","doi-asserted-by":"crossref","first-page":"102298","DOI":"10.1016\/j.isci.2021.102298","article-title":"Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation","volume":"24","author":"Ganneru","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.isci.2023.105949_bib62","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.omtm.2021.08.005","article-title":"Immunological evaluation of an inactivated SARS-CoV-2 vaccine in rhesus macaques","volume":"23","author":"Chen","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.isci.2023.105949_bib63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.isci.2023.105949_bib64","doi-asserted-by":"crossref","first-page":"103938","DOI":"10.1016\/j.ebiom.2022.103938","article-title":"Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months","volume":"78","author":"Medigeshi","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2023.105949_bib65","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.105949_bib66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15585\/mmwr.mm7104e3","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.isci.2023.105949_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijid.2022.03.028","article-title":"Waning COVID-19 vaccine effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study","volume":"119","author":"Suah","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.isci.2023.105949_bib68","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.105949_bib69","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2023.105949_bib70","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/s41467-022-30864-w","article-title":"Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials","volume":"13","author":"Xin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2023.105949_bib71","doi-asserted-by":"crossref","first-page":"12038","DOI":"10.1038\/s41598-022-16097-3","article-title":"Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants","volume":"12","author":"Vadrevu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2023.105949_bib72","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1080\/23744235.2022.2097304","article-title":"Immunity waning after COVID vaccine booster vs. infection-better than expected","volume":"54","author":"Khoury","year":"2022","journal-title":"Infect. Dis."},{"key":"10.1016\/j.isci.2023.105949_bib73","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41591-021-01560-x","article-title":"Boosting immunity to COVID-19 vaccines","volume":"27","author":"Juno","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2023.105949_bib74","unstructured":"UK Health Security Agency. (2022). SARS-CoV-2 Variants of Concern and Variants under Investigation in England: Technical briefing 34. 14 January 2022. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1048395\/technical-briefing-34-14-january-2022.pdf."},{"key":"10.1016\/j.isci.2023.105949_bib75","article-title":"Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity","author":"Wu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.isci.2023.105949_bib76","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1080\/22221751.2021.1971569","article-title":"Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies","volume":"10","author":"Kozlovskaya","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.isci.2023.105949_bib77","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.3390\/v13122440","article-title":"Protective immunity against gamma and zeta variants after inactivated SARS-CoV-2 virus immunization","volume":"13","author":"Fumagalli","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2023.105949_bib78","doi-asserted-by":"crossref","first-page":"102054","DOI":"10.1016\/j.isci.2021.102054","article-title":"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model","volume":"24","author":"Mohandas","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.isci.2023.105949_bib79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","article-title":"Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2","volume":"182","author":"Jiang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.isci.2023.105949_bib80","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","article-title":"A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate","volume":"590","author":"Sanchez-Felipe","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2023.105949_bib81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41541-021-00321-8","article-title":"Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters","volume":"6","author":"Jia","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.isci.2023.105949_bib82","doi-asserted-by":"crossref","first-page":"e1009383","DOI":"10.1371\/journal.ppat.1009383","article-title":"Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model","volume":"17","author":"Kurup","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2023.105949_bib83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-021-00352-1","article-title":"A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19","volume":"6","author":"Malherbe","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.isci.2023.105949_bib84","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4049\/jimmunol.2100421","article-title":"Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity","volume":"207","author":"Matchett","year":"2021","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.isci.2023.105949_bib85","doi-asserted-by":"crossref","first-page":"eabh0755","DOI":"10.1126\/scitranslmed.abh0755","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models","volume":"13","author":"van Doremalen","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2023.105949_bib86","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/vaccines9040340","article-title":"A whole virion vaccine for COVID-19 produced via a novel inactivation method and preliminary demonstration of efficacy in an animal challenge model","volume":"9","author":"Ragan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.isci.2023.105949_bib87","doi-asserted-by":"crossref","first-page":"e719","DOI":"10.1093\/cid\/ciab083","article-title":"Absence of vaccine-enhanced disease with unexpected positive protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inactivated vaccine given within 3 Days of virus challenge in Syrian hamster model","volume":"73","author":"Li","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.isci.2023.105949_bib88","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/vaccines9030214","article-title":"Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine: preclinical studies","volume":"9","author":"Kandeil","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.isci.2023.105949_bib89","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-021-21639-w","article-title":"Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques","volume":"12","author":"Yadav","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2023.105949_bib90","unstructured":"WHO. COVID-19 Landscape of Novel Coronavirus Candidate Vaccine Development Worldwide - 15 April 2022. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"10.1016\/j.isci.2023.105949_bib91","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/v13061115","article-title":"The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation","volume":"13","author":"Bai","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2023.105949_bib92","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.105949_bib93","doi-asserted-by":"crossref","first-page":"109664","DOI":"10.1016\/j.celrep.2021.109664","article-title":"Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2","volume":"36","author":"Dangi","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2023.105949_bib94","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104241118","article-title":"Ongoing global and regional adaptive evolution of SARS-CoV-2","volume":"118","author":"Rochman","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2023.105949_bib95","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of covid-19 vaccines against the B.1.617.2 (delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.105949_bib96","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/22221751.2021.1969291","article-title":"Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study","volume":"10","author":"Li","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.isci.2023.105949_bib97","doi-asserted-by":"crossref","first-page":"612.e1-e7","DOI":"10.1016\/j.cmi.2021.11.010","article-title":"Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study","volume":"28","author":"Chia","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.isci.2023.105949_bib98","doi-asserted-by":"crossref","first-page":"101143","DOI":"10.1016\/j.eclinm.2021.101143","article-title":"An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam","volume":"41","author":"Chau","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.isci.2023.105949_bib99","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(22)00056-3","article-title":"Omicron severity: milder but not mild","volume":"399","author":"Nealon","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.105949_bib100","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.105949_bib101","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1056\/NEJMc2119236","article-title":"SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons","volume":"386","author":"R\u00f6ssler","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.105949_bib102","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMc2119358","article-title":"Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection","volume":"386","author":"Nemet","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.105949_bib103","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41421-022-00375-5","article-title":"Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination","volume":"8","author":"Yu","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.isci.2023.105949_bib104","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1093\/cid\/ciab1041","article-title":"Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients","volume":"75","author":"Lu","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.isci.2023.105949_bib105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/22221751.2022.2030200","article-title":"Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.isci.2023.105949_bib106","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2023.105949_bib107","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1126\/science.abq0203","article-title":"Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines","volume":"377","author":"Bowen","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.isci.2023.105949_bib108","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1016\/j.cell.2021.09.010","article-title":"COVID-19 vaccines: keeping pace with SARS-CoV-2 variants","volume":"184","author":"Cevik","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.isci.2023.105949_bib109","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2023.105949_bib110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.105949_bib111","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/vaccines10010075","article-title":"Analysis of neutralization titers against SARS-CoV-2 in health-care workers vaccinated with prime-boost mRNA-mRNA or vector-mRNA COVID-19 vaccines","volume":"10","author":"S\u00f8lund","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.isci.2023.105949_bib112","doi-asserted-by":"crossref","first-page":"e0268020","DOI":"10.1128\/AAC.02680-20","article-title":"Hepatitis C virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of SARS-CoV-2 in\u00a0vitro","volume":"65","author":"Gammeltoft","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2023.105949_bib113","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/elsc.201600153","article-title":"Specific ion effects on the particle size distributions of cell culture-derived influenza A virus particles within the Hofmeister series","volume":"17","author":"Pieler","year":"2017","journal-title":"Eng. Life Sci."},{"key":"10.1016\/j.isci.2023.105949_bib114","doi-asserted-by":"crossref","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Euro Surveill."},{"key":"10.1016\/j.isci.2023.105949_bib115","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/JVI.02667-09","article-title":"Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in\u00a0vivo pathogenesis studies","volume":"84","author":"Gottwein","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2023.105949_bib116","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.isci.2023.105949_bib117","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/vaccines8020294","article-title":"Specific antibodies induced by immunization with hepatitis B virus-like particles carrying hepatitis C virus envelope glycoprotein 2 epitopes show differential neutralization efficiency","volume":"8","author":"Czarnota","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.isci.2023.105949_bib118","doi-asserted-by":"crossref","first-page":"103519","DOI":"10.1016\/j.ebiom.2021.103519","article-title":"Neutralisation titres against SARS-CoV-2 are sustained 6\u00a0months after onset of symptoms in individuals with mild COVID-19","volume":"71","author":"Underwood","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2023.105949_bib119","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0300985812469638","article-title":"Histologic and immunohistochemical classification of 41 bovine adrenal gland neoplasms","volume":"50","author":"Grossi","year":"2013","journal-title":"Vet. Pathol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:19:10Z","timestamp":1787260750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004223000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2589004223000263"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2023.105949","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2023.105949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"105949"}}